Abstract:A number of published papers have investigated the relation between atrial fibrillation (AF) and clinical outcomes of patients with coronavirus disease 2019 (COVID-19). However, the conclusions drawn from previous studies are not consistent. For instance, some studies observed that AF was significantly associated with an increased risk of mortality among COVID-19 patients,1Peltzer B Manocha KK Ying X Kirzner J Ip JE Thomas G Liu CF Markowitz SM Lerman BB Safford MM Goyal P Cheung JW. Outcomes and mortality associated with atrial arrhythmias among patients hospitalized with COVID-19.J Cardiovasc Electrophysiol. 2020; 31: 3077-3085Crossref PubMed Scopus (63) Google Scholar, 2Reilev M Kristensen KB Pottegard A Lund LC Hallas J Ernst MT Christiansen CF Sorensen HT Johansen NB Brun NC Voldstedlund M Stovring H Thomsen MK Christensen S Gubbels S Krause TG Molbak K Thomsen RW. Characteristics and predictors of hospitalization and death in the first 11 122 cases with a positive RT-PCR test for SARS-CoV-2 in Denmark: a nationwide cohort.Int J Epidemiol. 2020; 49: 1468-1481Crossref PubMed Scopus (187) Google Scholar, 3Rodilla E Saura A Jimenez I Mendizabal A Pineda-Cantero A Lorenzo-Hernandez E Fidalgo-Montero MDP Lopez-Cuervo JF Gil-Sanchez R Rabadan-Pejenaute E Abella-Vazquez L Giner-Galvan V Solis-Marquinez MN Boixeda R Pena-Fernandez A Carrasco-Sanchez FJ Gonzalez-Moraleja J Torres-Pena JD Guisado-Espartero ME Escobar-Sevilla J Guzman-Garcia M Martin-Escalante MD Martinez-Gonzalez AL Casas-Rojo JM Gomez-Huelgas R. Association of hypertension with all-cause mortality among hospitalized patients with COVID-19.J Clin Med. 2020; 9https://doi.org/10.3390/jcm9103136Crossref PubMed Scopus (56) Google Scholar while several other studies reported opposite results that there was no significant relation between AF and unfavorable outcomes of COVID-19 patients.4Izurieta HS Graham DJ Jiao Y Hu M Lu Y Wu Y Chillarige Y Wernecke M Menis M Pratt D Kelman J Forshee R. Natural history of COVID-19: risk factors for hospitalizations and deaths among >26 million U.S. Medicare beneficiaries.J Infect Dis. 2020; https://doi.org/10.1093/infdis/jiaa767Crossref Scopus (45) Google Scholar, 5Lala A Johnson KW Januzzi JL Russak AJ Paranjpe I Richter F Zhao S Somani S Van Vleck T Vaid A Chaudhry F De Freitas JK Fayad ZA Pinney SP Levin M Charney A Bagiella E Narula J Glicksberg BS Nadkarni G Mancini DM Fuster V Mount Sinai CIC Prevalence and impact of myocardial injury in patients hospitalized with COVID-19 infection.J Am Coll Cardiol. 2020; 76: 533-546Crossref PubMed Scopus (495) Google Scholar, 6van Gerwen M Alsen M Little C Barlow J Genden E Naymagon L Tremblay D. Risk factors and outcomes of COVID-19 in New York City; a retrospective cohort study.J Med Virol. 2021; 93: 907-915Crossref PubMed Scopus (76) Google Scholar Several confounding factors such as gender, age and pre-existing medical disorders (diabetes, hypertension, autoimmune diseases, chronic kidney disease, and chronic obstructive pulmonary disease, etc.) have been reported to significantly influence the clinical outcomes of COVID-19 patients,7Barek MA Aziz MA Islam MS. Impact of age, sex, comorbidities and clinical symptoms on the severity of COVID-19 cases: a meta-analysis with 55 studies and 10014 cases.Heliyon. 2020; 6: e05684Abstract Full Text Full Text PDF PubMed Scopus (114) Google Scholar, 8Biswas M Rahaman S Biswas TK Haque Z Ibrahim B. Association of sex, age, and comorbidities with mortality in COVID-19 Patients: a systematic review and meta-analysis.Intervirology. 2020; : 1-12PubMed Google Scholar, 9Liang X Shi L Wang Y Xiao W Duan G Yang H Wang Y. The association of hypertension with the severity and mortality of COVID-19 patients: evidence based on adjusted effect estimates.J Infect. 2020; 81: e44-e47Abstract Full Text Full Text PDF PubMed Scopus (49) Google Scholar, 10Liang X Xu J Xiao W Shi L Yang H. The association of diabetes with COVID-19 disease severity: evidence from adjusted effect estimates.Hormones. 2020; https://doi.org/10.1007/s42000-020-00259-xCrossref PubMed Scopus (15) Google Scholar, 11Xiao W Xu J Liang X Shi L Zhang P Wang Y Yang H. Relationship between chronic kidney disease and adverse outcomes of coronavirus disease 2019: a meta-analysis based on adjusted risk estimates.Int Urol Nephrol. 2021; https://doi.org/10.1007/s11255-020-02748-9Crossref Scopus (3) Google Scholar, 12Yang H Xu J Liang X Shi L Wang Y. Autoimmune diseases are independently associated with COVID-19 severity: evidence based on adjusted effect estimates.J Infect. 2020; https://doi.org/10.1016/j.jinf.2020.12.025Abstract Full Text Full Text PDF Scopus (16) Google Scholar, 13Xiao WW Xu J Shi L Wang YD Yang HY. Is chronic obstructive pulmonary disease an independent predictor for adverse outcomes in coronavirus disease 2019 patients?.Eur Rev Med Pharmacol Sci. 2020; 24: 11421-11427PubMed Google Scholar suggesting that these factors might have significant impacts on the relation between AF and unfavorable outcomes of COVID-19 patients. In this meta-analysis, the pooled effect size was estimated on the basis of adjusted effect estimates reported in published papers. We systematically searched PubMed, Web of Science, and EMBASE databases to identify all potential documents published between January 1, 2020 and December 24, 2020, using the following keywords and terms: “severe acute respiratory syndrome coronavirus-2” or “SARS-CoV-2” or “coronavirus disease 2019” or “COVID-19” or “2019 novel coronavirus” or “2019-nCoV” and “atrial fibrillation” and “severity” or “severe” or “critical” or “mortality” or “death” or “fatality” or “intensive care unit” or “mechanical ventilation”. Studies were eligibly included if they met the following criteria: (1) studies reporting laboratory-confirmed COVID-19 patients; (2) articles should be peer-reviewed; (3) articles should be published in English; (4) the adjusted effect estimate on the relation between AF and unfavorable outcomes of COVID-19 patients are available. Accordingly, studies were excluded if they were: (1) repeated studies, review papers, comments, errata, protocols and case reports; (2) articles reporting crude effect size; (3) articles with insufficient data; (4) in vitro studies or animal studies. Two investigators independently extracted the basic characteristics including name of authors, country and/or region, number of cases, percentage of male, age (mean ± standard deviation or median (interquartile range), study design, adjusted effect size and outcomes. In case of disagreement, a third investigator was consulted and made a final decision. Statistical analysis was carried out using Stata 12.1 software. I2 statistic and Cochran's Q test were adopted in the assessment of heterogeneity among the included studies. The pooled effect size and 95% confidence interval (CI) were calculated to estimate the relation between AF and unfavorable outcomes of COVID-19 patients. A fixed-effects analysis was conducted if there was no heterogeneity (I2 < 50% or p > 0.1), otherwise, a random-effects analysis was carried out (I2 > 50% or p < 0.1). Leave-one-out sensitivity analysis was performed to assess the stability of our results. Publication bias was evaluated by Begg's rank correlation test and Egger's linear regression test. Subgroup analysis and meta-regression analysis were also performed to probe the source of heterogeneity. A p-value < 0.05 was deemed statistically significant. Nine hundred and sixteen potentially relevant studies were screened according to the inclusion and exclusion criteria. Finally, 23 studies with 108,745 COVID-19 patients1Peltzer B Manocha KK Ying X Kirzner J Ip JE Thomas G Liu CF Markowitz SM Lerman BB Safford MM Goyal P Cheung JW. Outcomes and mortality associated with atrial arrhythmias among patients hospitalized with COVID-19.J Cardiovasc Electrophysiol. 2020; 31: 3077-3085Crossref PubMed Scopus (63) Google Scholar, 2Reilev M Kristensen KB Pottegard A Lund LC Hallas J Ernst MT Christiansen CF Sorensen HT Johansen NB Brun NC Voldstedlund M Stovring H Thomsen MK Christensen S Gubbels S Krause TG Molbak K Thomsen RW. Characteristics and predictors of hospitalization and death in the first 11 122 cases with a positive RT-PCR test for SARS-CoV-2 in Denmark: a nationwide cohort.Int J Epidemiol. 2020; 49: 1468-1481Crossref PubMed Scopus (187) Google Scholar, 3Rodilla E Saura A Jimenez I Mendizabal A Pineda-Cantero A Lorenzo-Hernandez E Fidalgo-Montero MDP Lopez-Cuervo JF Gil-Sanchez R Rabadan-Pejenaute E Abella-Vazquez L Giner-Galvan V Solis-Marquinez MN Boixeda R Pena-Fernandez A Carrasco-Sanchez FJ Gonzalez-Moraleja J Torres-Pena JD Guisado-Espartero ME Escobar-Sevilla J Guzman-Garcia M Martin-Escalante MD Martinez-Gonzalez AL Casas-Rojo JM Gomez-Huelgas R. Association of hypertension with all-cause mortality among hospitalized patients with COVID-19.J Clin Med. 2020; 9https://doi.org/10.3390/jcm9103136Crossref PubMed Scopus (56) Google Scholar, 4Izurieta HS Graham DJ Jiao Y Hu M Lu Y Wu Y Chillarige Y Wernecke M Menis M Pratt D Kelman J Forshee R. Natural history of COVID-19: risk factors for hospitalizations and deaths among >26 million U.S. Medicare beneficiaries.J Infect Dis. 2020; https://doi.org/10.1093/infdis/jiaa767Crossref Scopus (45) Google Scholar, 5Lala A Johnson KW Januzzi JL Russak AJ Paranjpe I Richter F Zhao S Somani S Van Vleck T Vaid A Chaudhry F De Freitas JK Fayad ZA Pinney SP Levin M Charney A Bagiella E Narula J Glicksberg BS Nadkarni G Mancini DM Fuster V Mount Sinai CIC Prevalence and impact of myocardial injury in patients hospitalized with COVID-19 infection.J Am Coll Cardiol. 2020; 76: 533-546Crossref PubMed Scopus (495) Google Scholar, 6van Gerwen M Alsen M Little C Barlow J Genden E Naymagon L Tremblay D. Risk factors and outcomes of COVID-19 in New York City; a retrospective cohort study.J Med Virol. 2021; 93: 907-915Crossref PubMed Scopus (76) Google Scholar,14Atkins JL Masoli JAH Delgado J Pilling LC Kuo CL Kuchel GA Melzer D. Preexisting comorbidities predicting COVID-19 and mortality in the UK biobank community cohort.J Gerontol A Biol Sci Med Sci. 2020; 75: 2224-2230Crossref PubMed Scopus (302) Google Scholar, 15Hippisley-Cox J Tan PS Coupland C. Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study including 8.3 million people.Heart. 2020; https://doi.org/10.1136/heartjnl-2020-318312Crossref Scopus (8) Google Scholar, 16Peterson E Lo KB DeJoy R Salacup G Pelayo J Bhargav R Gul F Albano J Azmaiparashvili Z Amanullah A Patarroyo-Aponte G. The relationship between coronary artery disease and clinical outcomes in COVID-19: a single-center retrospective analysis.Coron Artery Dis. 2020; https://doi.org/10.1097/MCA.0000000000000934Crossref PubMed Scopus (23) Google Scholar, 17Perez-Guzman PN Daunt A Mukherjee S Crook P Forlano R Kont MD Lochen A Vollmer M Middleton P Judge R Harlow C Soubieres A Cooke G White PJ Hallett TB Aylin P Ferguson N Hauck K Thursz MR Nayagam S. Clinical characteristics and predictors of outcomes of hospitalized patients with COVID-19 in a multi-ethnic London NHS Trust: a retrospective cohort study.Clin Infect Dis. 2020; https://doi.org/10.1093/cid/ciaa1091Crossref Scopus (43) Google Scholar, 18Elias P Poterucha TJ Jain SS Sayer G Raikhelkar J Fried J Clerkin K Griffin J DeFilippis EM Gupta A Lawlor M Madhavan M Rosenblum H Roth ZB Natarajan K Hripcsak G Perotte A Wan EY Saluja A Dizon J Ehlert F Morrow JP Yarmohammadi H Kumaraiah D Redfors B Gavin N Kirtane A Rabbani L Burkhoff D Moses J Schwartz A Leon M Uriel N. The prognostic value of electrocardiogram at presentation to emergency department in patients with COVID-19.Mayo Clin Proc. 2020; 95: 2099-2109Abstract Full Text Full Text PDF PubMed Scopus (39) Google Scholar, 19Rodriguez-Molinero A Galvez-Barron C Minarro A Macho O Lopez GF Robles MT Dapena MD Martinez S Mila Rafols N Monaco EE Hidalgo Garcia A CSAPG C-RGoAssociation between COVID-19 prognosis and disease presentation, comorbidities and chronic treatment of hospitalized patients.PloS one. 2020; 15e0239571Crossref PubMed Scopus (40) Google Scholar, 20Clift AK Coupland CAC Keogh RH Diaz-Ordaz K Williamson E Harrison EM Hayward A Hemingway H Horby P Mehta N Benger J Khunti K Spiegelhalter D Sheikh A Valabhji J Lyons RA Robson J Semple MG Kee F Johnson P Jebb S Williams T Hippisley-Cox J. Living risk prediction algorithm (QCOVID) for risk of hospital admission and mortality from coronavirus 19 in adults: national derivation and validation cohort study.Bmj. 2020; 371: m3731Crossref PubMed Scopus (364) Google Scholar, 21Alvarez-Garcia J Lee S Gupta A Cagliostro M Joshi AA Rivas-Lasarte M Contreras J Mitter SS LaRocca G Tlachi P Brunjes D Glicksberg BS Levin MA Nadkarni G Fayad Z Fuster V Mancini D Lala A. Prognostic impact of prior heart failure in patients hospitalized with COVID-19.J Am Coll Cardiol. 2020; 76: 2334-2348Crossref PubMed Scopus (125) Google Scholar, 22Tang O Bigelow BF Sheikh F Peters M Zenilman JM Bennett R Katz MJ. Outcomes of nursing home COVID-19 patients by initial symptoms and comorbidity: results of universal testing of 1970 residents.J Am Med Dir Assoc. 2020; 21 (e1761): 1767-1773Abstract Full Text Full Text PDF PubMed Scopus (30) Google Scholar, 23Shah C Grando DJ Rainess RA Ayad L Gobran E Benson P Neblett MT Nookala V. Factors associated with increased mortality in hospitalized COVID-19 patients.Ann Med Surg (Lond). 2020; 60: 308-313Crossref PubMed Scopus (11) Google Scholar, 24Tomasoni D Inciardi RM Lombardi CM Tedino C Agostoni P Ameri P Barbieri L Bellasi A Camporotondo R Canale C Carubelli V Carugo S Catagnano F Dalla Vecchia LA Danzi GB Di Pasquale M Gaudenzi M Giovinazzo S Gnecchi M Iorio A La Rovere MT Leonardi S Maccagni G Mapelli M Margonato D Merlo M Monzo L Mortara A Nuzzi V Piepoli M Porto I Pozzi A Sarullo F Sinagra G Volterrani M Zaccone G Guazzi M Senni M Metra M Impact of heart failure on the clinical course and outcomes of patients hospitalized for COVID-19. Results of the Cardio-COVID-Italy multicentre study.Eur J Heart Fail. 2020; https://doi.org/10.1002/ejhf.2052Crossref Scopus (90) Google Scholar, 25Polverino F Stern DA Ruocco G Balestro E Bassetti M Candelli M Cirillo B Contoli M Corsico A D'Amico F D'Elia E Falco G Gasparini S Guerra S Harari S Kraft M Mennella L Papi A Parrella R Pelosi P Poletti V Polverino M Tana C Terribile R Woods JC Di Marco F Martinez FD Comorbidities, cardiovascular therapies, and COVID-19 mortality: a nationwide, Italian Observational Study (ItaliCO).Front Cardiovasc Med. 2020; 7585866Crossref PubMed Scopus (57) Google Scholar, 26Loffi M Piccolo R Regazzoni V Di Tano G Moschini L Robba D Quinzani F Esposito G Franzone A Danzi GB. Coronary artery disease in patients hospitalised with Coronavirus disease 2019 (COVID-19) infection.Open heart. 2020; 7https://doi.org/10.1136/openhrt-2020-001428Crossref PubMed Scopus (18) Google Scholar, 27Canevelli M Palmieri L Raparelli V Lo Noce C Colaizzo E Tiple D Vaianella L Vanacore N Brusaferro S Onder G Italian National Institute of Health C-MGPrevalence and clinical correlates of dementia among COVID-19-related deaths in Italy.Alzheimers Dement (Amst). 2020; 12: e12114PubMed Google Scholar, 28Rossi L Malagoli A Biagi A Zanni A Sticozzi C Comastri G Pannone L Gandolfi S Vergara P Villani GQ. Renin-angiotensin system inhibitors and mortality in patients with COVID-19.Infection. 2020; https://doi.org/10.1007/s15010-020-01550-0Crossref Scopus (15) Google Scholar, 29Gue YX Tennyson M Gao J Ren S Kanji R Gorog DA. Development of a novel risk score to predict mortality in patients admitted to hospital with COVID-19.Sci Rep. 2020; 10: 21379Crossref PubMed Scopus (26) Google Scholar, 30Lano G Braconnier A Bataille S Cavaille G Moussi-Frances J Gondouin B Bindi P Nakhla M Mansour J Halin P Levy B Canivet E Gaha K Kazes I Noel N Wynckel A Debrumetz A Jourde-Chiche N Moal V Vial R Scarfogliere V Bobot M Gully M Legris T Pelletier M Sallee M Burtey S Brunet P Robert T Rieu P. Risk factors for severity of COVID-19 in chronic dialysis patients from a multicentre French cohort.Clin Kidney J. 2020; 13: 878-888Crossref PubMed Google Scholar were eligibly included in the present quantitative meta-analysis. The study characteristics are summarized in Table 1. Ten studies came from United States of America (USA) and 13 studies were from Europe (5 from United Kingdom, 4 from Italy, 2 from Spain and 1 each from Denmark and France). Results of our meta-analysis indicated that AF was significantly associated with an increased risk of unfavorable outcomes among COVID-19 patients (pooled effect size = 1.14, 95% CI: 1.03 to 1.26, p = 0.01; I2 = 63.9%, random-effects analysis; Figure 1). When the clinical outcomes were limited to death, there was still a significant relation between AF and COVID-19 mortality (pooled effect size = 1.13, 95% CI: 1.02 to 1.25). Subgroup analysis by effect estimate showed consistent results (pooled effect size = 1.12, 95% CI: 1.04 to 1.21 for hazard ratio (HR)-reported studies and pooled effect size = 1.18, 95% CI: 1.02 to 1.37 for odds ratio (OR)-reported studies). Inconsistent results were observed in the subgroup analyses by sample size (pooled effect size = 1.14, 95% CI: 1.02 to 1.27 for ≥ 1,000 cases and pooled effect size = 1.12, 95% CI: 0.87 to 1.44 for < 1,000 cases), age (pooled effect size = 1.18, 95% CI: 1.06 to 1.31 for < 70 years old and pooled effect size = 1.06, 95% CI: 0.87 to 1.29 for ≥ 70 years old), percentage of male (pooled effect size = 1.26, 95% CI: 1.06 to 1.51 for ≥ 60% and pooled effect size = 1.09, 95% CI: 0.97 to 1.22 for < 60%) and region (pooled effect size = 1.21, 95% CI: 1.08 to 1.35 for Europe and pooled effect size = 1.06, 95% CI: 0.90 to 1.24 for USA). We observed no significant relation between AF and unfavorable outcomes among COVID-19 patients in the subgroup analysis of study design (pooled effect size = 1.08, 95% CI: 0.97 to 1.22 for retrospective study, pooled effect size = 1.27, 95% CI: 0.95 to 1.70 for observational cohort study and pooled effect size = 1.34, 95% CI: 0.92 to 1.96 for the others). Sensitivity analysis showed that our results were stable and reliable since omitting each study one by one had no obvious effects on the overall effect size (Figure 1). There was no obvious publication bias assessed by Begg's test (p = 0.428, Figure 1) and Egger's test (p = 0.081, Figure 1). Meta-regression analysis exhibited that the tested variables such as sample size, age, percentage of male, region, study design, and effect estimate might not be the source of heterogeneity (data not shown).Table 1Main characteristics of the studies included in this meta-analysisAuthorCountryCasesMale (%)Age§Study designAdjusted-effect size (95% CI)Lala AUSA273659.6%66.4Retrospective studyOR: 1.08 (0.81-1.44)Atkins JLUK50761.3%74.3±4.5UK biobank cohortOR: 1.63 (0.98-2.71)van Gerwen MUSA370355.3%56.8±18.2Retrospective studyOR: 1.19 (0.87-1.62)Hippisley-Cox JUK1948648.1%62.18±20.84Prospective studyHR: 0.87 (0.55-1.39)Peterson EUSA35551%66.21±14.21Retrospective studyOR: 0.475 (0.190-1.188)Perez-Guzman PNUK61462.2%69 (25)Retrospective studyOR: 1.25 (0.73-2.13)Reilev MDenmark1112242.2%48 (33-62)Population-based studyOR: 1.6 (1.2-2.0)Rodilla ESpain1222657.4%67.5±16.1Retrospective studyOR: 1.2 (1.01-1.33)Elias PUSA125854%61.6±18.4Retrospective studyOR: 2.54 (1.05-6.2)Peltzer BUSA105362.3%62±17Retrospective studyOR: 2.16 (1.33-3.52)Rodriguez-Molinero ASpain41856.9%65.4±16.6Observational cohort studyOR: 1.86 (0.86-4.02)Clift AKUK1077655.3%69.63±17.91Observational cohort studyHR: 1.18 (1.04-1.34)HR: 1.11 (1.00-1.24)Alvarez-Garcia JUSA634955.1%63.5±18Retrospective studyHR: 0.91 (0.63-1.31)Tang OUSA75239.9%71.16±51.68Retrospective studyHR: 0.86 (0.57-1.30)Shah CUSA48756.1%68.42±16.70Retrospective studyOR: 0.91 (0.50-1.65)Tomasoni DItaly69269.5%67.4±13.2Retrospective studyHR: 1.27 (0.73-2.23)Polverino FUSA317968.3%69.0 (57-78)Retrospective studyOR: 0.97 (0.69-1.36)Loffi MItaly125263.7%64.7±15.5Retrospective studyHR: 1.09 (0.75-1.58)Canevelli MItaly262167.6%78.16±10.51Retrospective studyOR: 0.99 (0.72-1.37)Rossi LItaly59066.1%76.2 (68.2-82.6)Retrospective studyHR: 1.390 (0.925-1.885)Gue YXUK48638.7%73.42±15.97Retrospective studyOR: 0.49 (0.35-1.58)Izurieta HSUSA2796148.8%79.07±10.15Retrospective studyOR: 0.97 (0.92-1.01)Lano GFrance12265%73.5 (64.2-81.2)Observational cohort studyOR: 1.838 (0.751-4.481)Note: § indicates the values are presented as mean ± standard deviation (SD) or median (interquartile range, IQR); CI, confidence interval; HR, hazard ratio; OR, odds ratio; UK, the United Kingdom; USA, the United States of America. Open table in a new tab Note: § indicates the values are presented as mean ± standard deviation (SD) or median (interquartile range, IQR); CI, confidence interval; HR, hazard ratio; OR, odds ratio; UK, the United Kingdom; USA, the United States of America. Limitations: (1) All the included studies came from USA and Europe. (2) Because medications for COVID-19 were not clearly reported in most of the included studies, we did not address the effects of these factors on the relation between AF and unfavorable outcomes of COVID-19 patients. (3) The adjusted risk factors are variable across the included studies. (4) Most of the studies are retrospective, further meta-analyses based on prospective studies with large sample size are warranted to verify our findings when more data are available. In conclusion, our study demonstrates that AF was significantly associated with an increased risk of unfavorable outcomes among COVID-19 patients, especially for death. Yadong Wang and Haiyan Yang designed the study. Xuan Liang and Jie Xu performed literature search. Haiyan Yang and Xuan Liang performed data extraction. Xuan Liang, Haiyan Yang, Jie Xu and Hongjie Hou performed statistical analyses. Haiyan Yang, Xuan Liang and Yadong Wang wrote and reviewed the manuscript. All the authors approved the final version of the manuscript. The authors declare that they have no any potential conflict of interest regarding this submitted manuscript. We would like to thank Li Shi, Ying Wang, Peihua Zhang, Yang Li, Jian Wu and Wenwei Xiao (All are from Department of Epidemiology, School of Public Health, Zhengzhou University) for their kind help in searching articles and collecting data, and valuable suggestions for data analysis.

New-Onset Atrial Fibrillation and Early Mortality Rate in COVID-19 Patients: Association with IL-6 Serum Levels and Respiratory Distress

Pre-existing Atrial Fibrillation is Associated with Increased Mortality in COVID-19 Patients

Meta-Analysis of Atrial Fibrillation in Patients With COVID-19

Association of New-Onset Atrial Fibrillation With All-Cause Mortality in COVID-19 Patients

Increased interleukin-6 levels are associated with atrioventricular conduction delay in severe COVID-19 patients

Contribution of Atrial Fibrillation to In-Hospital Mortality in Patients With COVID-19

New-Onset Atrial Fibrillation in Patients Hospitalized With COVID-19: Results From the American Heart Association COVID-19 Cardiovascular Registry

Permanent and persistent atrial fibrillation are independent risk factors of mortality after severe COVID-19

A pooled analysis of the incidence and mortality risk of atrial fibrillation in patients with COVID-19

Permanent and Persistent Atrial Fibrillations Are Independent Risk Factors of Mortality after Severe COVID-19

Prevalence of Atrial Fibrillation and Associated Mortality Among Hospitalized Patients With COVID-19: A Systematic Review and Meta-Analysis

Association between electrocardiographic features and mortality in COVID-19 patients

COVID-19 patients with acute pulmonary embolism have a higher mortality risk: systematic review and meta-analysis based on Italian cohorts.

Complications of new-onset atrial fibrillation in critically ill COVID-19 patients admitted to the intensive care unit (ICU): a meta-analysis

Emergence of Atrial Fibrillation and Flutter in COVID-19 Patients: A Retrospective Cohort Study

Atrial fibrillation is a risk factor for major adverse cardiovascular events in COVID-19

Incidence and mortality risk in coronavirus disease 2019 patients complicated by acute cardiac injury: systematic review and meta-analysis

IL-6 and D-dimer Levels at Admission Predict Cardiac Injury and Early Mortality During SARS-CoV-2 Infection

Nationwide Trends in Hospitalizations for Atrial Fibrillation and Flutter in the United States before and during the Outbreak of the COVID-19 Pandemic

A systematic review and meta‐analysis of new‐onset atrial fibrillation in the context of COVID‐19 infection

COVID-19 increases the risk for the onset of atrial fibrillation in hospitalized patients